BioSpace News Archive

Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis.

Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests today announced that on July 27, 2022, the Board of Directors of Lucira granted inducement awards consisting of 1,051,405 restricted stock units (“RSUs”) under Lucira’s 2022 Inducement Plan.

HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results and provides updates on key clinical and commercial developments for the six months ended June 30, 2022.

A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography technology, which can transform patient’s treatment and care of basal cell carcinomas.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced that the first patient has been dosed in the Phase 2 “Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights.

Covaris, LLC (“Covaris” or “the Company”), a manufacturer of advanced tools enabling life science innovations, announced today that it has appointed Annemarie Watson as Chief Executive Officer, effective immediately.

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.